Introduction {#section1-1756283X16666806}
============

Syndromic and nonsyndromic mitochondrial disorders (MIDs) are in the majority of cases multisystem conditions \[mitochondrial multiorgan disorder syndrome (MIMODS)\], manifesting in each organ of the body but with markedly different prevalence and high variability \[[@bibr27-1756283X16666806]\]. The organs most frequently affected are the muscle, the central nervous system (CNS), the endocrine glands, the eyes, the ears, and the heart \[[@bibr33-1756283X16666806]\]. More rarely affected are the kidneys, gastrointestinal (GI) tract, bone marrow, arteries, bones, lungs, and the skin \[[@bibr36-1756283X16666806]\]. GI compromise may be due to an intestinal or extra-intestinal cause. Among syndromic MIDs, mitochondrial neurogastrointestinal encephalopathy (MNGIE) is the MID most well-known for its GI involvement \[[@bibr45-1756283X16666806]\]. MIDs may also mimic cycling vomiting syndrome where mitochondrial dysfunction may play a pathogenetic role \[[@bibr39-1756283X16666806]\]. It is estimated that more than 50% of the MIDs present with some form of GI compromise, but GI manifestations of MIDs are often not well appreciated. However, recognition of GI manifestation may facilitate the diagnosis of MIDs. This review aimed at summarizing and discussing current knowledge and recent findings concerning the clinical presentation, diagnosis, and treatment of GI involvement in MIDs and attempted to reinforce to the gastroenterologist that GI manifestations of MIDs should be managed symptomatically.

Methods {#section2-1756283X16666806}
=======

Data for this review were identified by searches of MEDLINE, Current Contents, EMBASE, Web of Science, Web of Knowledge, LILACS, SCOPUS, and Google Scholar for references of relevant articles using the search terms 'appetite', 'sicca syndrome', 'dry mouth', 'dysphagia', 'vomiting', 'reflux', 'pancreatitis', 'pancreatic cyst', 'liver cysts', 'hepatopathy', 'steatosis hepatis', 'intestinal pseudo-obstruction', 'megacolon', 'pancreas lipomatosis', 'diarrhea', 'constipation', in combination with 'mtDNA', 'respiratory chain', 'MID', 'MNGIE', 'cycling vomiting', and 'neuromuscular'. Randomized (blinded or open label) clinical trials, longitudinal studies, case series, and case reports were considered. Abstracts and reports from meetings were not included. Only articles in English, French, Spanish, or German and published between 1966 and 2015 were included. Appropriate papers were studied and discussed for their usefulness to be incorporated in this review.

![Overview about about the selection process of the included literature.](10.1177_1756283X16666806-fig1){#fig1-1756283X16666806}

Results {#section3-1756283X16666806}
=======

The number of hits achieved by combining the applied search terms is given in [Table 1](#table1-1756283X16666806){ref-type="table"}. The main GI manifestations of MIDs include abnormalities of the GI hollow organs, such as poor appetite, gastroesophageal reflux and achalasia, constipation, dysphagia, vomiting, gastroparesis, diarrhea, and pseudo-obstruction, abnormalities of GI parenchymatous organs, such as aseptic pancreatitis, pancreatic cysts, pancreas lipomatosis, hepatopathy, steatosis hepatis, and liver cysts. The abnormalities are described in more detail in the following sections.

###### 

Number of hits achieved by combining the applied search terms in PubMed.

![](10.1177_1756283X16666806-table1)

                         mtDNA   RC     MID    MNGIE   CV   Neuromuscular
  ---------------------- ------- ------ ------ ------- ---- ---------------
  Appetite               13      26     31     0       0    24
  Sicca syndrome         5       10     37     0       0    33
  Dry mouth              4       7      20     0       0    75
  Dysphagia              52      40     87     3       0    837
  Vomiting               90      109    181    12      19   302
  Reflux                 6       18     14     1       0    242
  Pancreatitis           53      66     83     1       0    45
  Pancreatic cyst        1       4      2      0       0    3
  Liver cysts            33      20     35     0       0    3
  Hepatopathy            1519    1423   3278   10      0    486
  Steatosis              505     833    811    2       0    42
  Pseudo-obstruction     62      18     118    59      0    76
  Megacolon              6       5      11     2       0    51
  Pancreas lipomatosis   0       0      1      0       0    0
  Diarrhea               55      323    100    13      3    117
  Constipation           10      2      20     0       1    192
  Total                  2424    2904   4829   103     23   2528

CV, cycling vomiting; MID, mitochondrial disorder; MNGIE, mitochondrial neurogastrointestinal encephalopathy; mtDNA, mitochondrial DNA; RC, respiratory chain.

Abnormalities of gastrointestinal hollow organs {#section4-1756283X16666806}
-----------------------------------------------

### Poor appetite {#section5-1756283X16666806}

Poor appetite is a frequent GI manifestation of MIDs, which may result in weight loss, anorexia, or cachexia. Reduced appetite in children may result in trophic disturbance with poor weight gain \[[@bibr17-1756283X16666806]\]. Poor appetite may have a CNS cause, may be due to mood disturbance, or may be due to GI compromise. CNS causes may be leukoencephalopathy, dementia, or cognitive impairment. If CNS abnormalities cause poor appetite this may lead to dysphagia. GI causes of poor appetite include dysmotility, pseudo-obstruction, hepatopathy, diarrhea, vomiting, pancreatitis, postprandial abdominal pain, or constipation. Syndromic MIDs and nonsyndromic MIDs may be associated with poor appetite. Among the syndromic MIDs poor appetite has been described in Kearns--Sayre syndrome (KSS) \[[@bibr46-1756283X16666806]\] and MNGIE \[[@bibr6-1756283X16666806]\] but also in other syndromes. There are also reports about nonsyndromic MIDs in which an eating disorder has been observed \[[@bibr26-1756283X16666806]\]. Loss of appetite was, for example, described in a 7-year-old girl carrying the sporadic mitochondrial DNA (mtDNA) mutation m.14739G\>A in the tRNA(Glu) gene \[[@bibr60-1756283X16666806]\]. If an MID manifests as autism in children, poor feeding is a frequent complaint. In patients with MNGIE poor appetite may result from bloating or abdominal pain \[[@bibr17-1756283X16666806]\]. In mice it has been shown that polg mutations are associated with reduced appetite thereby reducing the diabetic phenotype in these animals \[[@bibr37-1756283X16666806]\].

### Gastroesophageal sphincter dysfunction {#section6-1756283X16666806}

Gastroesophageal sphincter dysfunction may manifest as either gastroesophageal reflux or as achalasia. Gastroesophageal reflux is common in MIDs and is pathophysiologically the opposite of achalasia. Gastroesophageal reflux has been reported in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) \[[@bibr98-1756283X16666806]\], pontocerebellar hypoplasia (PCH) \[[@bibr80-1756283X16666806]\], MNGIE \[[@bibr44-1756283X16666806]\], and in nonsyndromic MIDs \[[@bibr8-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). Achalasia can occur at various locations along the GI tract, for example at the cricopharyngeal sphincter, the gastroesophageal sphincter, or the rectum. The cause of achalasia in MID patients remains unknown, but it can be speculated that affection of the smooth muscle cells by the metabolic defect or affection of the autonomic innervation with reduced parasympathetic tone may lead to sympathetic overinnervation or permanent contraction of smooth muscle cells. Possibly, achalasia results from a failure of smooth muscle fibers to relax which may cause a sphincter to remain closed and fail to open when needed. Achalasia is an exceedingly rare GI manifestation of pediatric MIDs but has been occasionally reported in adults \[[@bibr18-1756283X16666806]; [@bibr52-1756283X16666806]\]. In a 6-year-old female and a 6-month-old male with multiple mtDNA deletions, achalasia was the dominant feature and occurred at 3 and 7 years of age respectively \[[@bibr18-1756283X16666806]\]. Gastroesophageal reflux was found only in the male starting at age 6 months \[[@bibr18-1756283X16666806]\]. Cricopharyngeal achalasia has been reported in KSS patients and may lead to dysphagia \[[@bibr52-1756283X16666806]\]. Cricopharyngeal achalasia has been also reported in mtDNA deletion syndromes, such as KSS or chronic progressive external ophthalmoplegia (CPEO) \[[@bibr52-1756283X16666806]\].

###### 

GI manifestations in syndromic and nonsyndromic MIDs.

![](10.1177_1756283X16666806-table2)

  MID           PAP   DYP   VOM   GED   GPDE   PC   HP   IPO   COS   DAR
  ------------- ----- ----- ----- ----- ------ ---- ---- ----- ----- -----
  MELAS         −     −     \+    \+    −      \+   \+   \+    \+    −
  MERRF         −     \+    −     −     −      \+   \+   \+    −     −
  CPEO          −     \+    −     −     −      \+   \+   −     −     −
  KSS           −     \+    \+    \+    −      \+   −    −     −     −
  PS            −     \+    \+    −     −      \+   \+   −     −     −
  LHON          −     −     −     −     −      −    −    −     −     −
  NARP          −     −     −     −     −      −    −    −     −     −
  LS            −     \+    \+    −     −      −    \+   −     −     \+
  MIDD          −     −     −     −     −      \+   −    \+    \+    \+
  MLASA         −     −     −     −     −      −    −    −     −     −
  XLASA         −     −     −     −     −      −    −    −     −     −
  PCH           −     \+    −     \+    −      −    \+   −     −     −
  ADOA          −     −     −     −     −      −    −    \+    \+    −
  ARCO          −     −     −     −     −      −    −    −     −     −
  ARSAL         −     −     −     −     −      −    −    −     −     −
  WS            −     \+    −     −     −      −    −    −     −     −
  MTS/DDS       −     \+    −     −     −      −    −    −     −     −
  DYTCA         −     −     −     −     −      −    −    −     −     −
  LBSL          −     −     −     −     −      −    −    −     −     −
  MEGDEL        −     −     −     −     −      −    \+   −     −     −
  SANDO (ANS)   −     \+    −     −     \+     −    −    −     −     −
  MIRAS (ANS)   −     −     −     −     −      −    \+   −     −     −
  MEMSA (ANS)   −     −     −     −     −      −    −    −     −     −
  SCAE (ANS)    −     −     −     −     −      −    −    −     −     −
  MNGIE (MDS)   \+    \+    \+    \+    \+     −    \+   \+    \+    \+
  IOSCA (MDS)   −     −     −     −     −      −    \+   −     −     −
  AHD (MDS)     −     −     \+    −     −      \+   \+   \+    \+    −
  HC-MDS        −     −     −     −     −      −    \+   −     −     −
  EM-MDS        −     −     −     −     −      −    \+   \+    −     \+
  MP-MDS        −     −     −     −     −      −    \+   −     −     −
  MCHS (MDS)    −     −     \+    −     −      −    \+   −     −     −
  Ns MID        \+    \+    \+    \+    \+     \+   \+   \+    \+    \+

ADOA, autosomal dominant optic atrophy; AHD, Alpers--Huttenlocher disease; ANS, ataxia neuropathy spectrum; ARCO, autosomal recessive cardiomyopathy and ophthalmoplegia; ARSAL, autosomal recessive spastic ataxia with leukoencephalopathy; COS, constipation; CPEO, chronic progressive external ophthalmoplegia; DAR, diarrhea; DYP, dysphagia; DYTCA, dystonia ataxia syndrome; EM-MDS, encephalomyopathic MDS; GED, gastro-esophageal sphincter dysfunction; GPDE, gastroparesis and delayed emptying; HC-MDS, hepato-cerebral mitochondrial depletion syndrome; HP, hepatopathy; IOSCA, infantile-onset spinocerebellar ataxia; IPO, intestinal pseudo-obstruction; KSS, Kearns--Sayre syndrome; LBSL, leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation; LHON, Leber's hereditary optic neuropathy; LS, Leigh syndrome; MCHS, myo-cerebro-hepatopathy spectrum; MDS, mitochondrial depletion syndrome; MELAS, mitochondrial encephalopathy, lactacidosis, and stroke-like episodes; MEGDEL, 3-methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy and Leigh-like syndrome; MEMSA, myoclonus, epilepsy, myopathy, and sensory ataxia; MERRF, myoclonic epilepsy with ragged red fibers; MIDD, maternally inherited diabetes and deafness; MIRAS, mitochondrial recessive ataxia syndrome; MNGIE, mitochondrial neurogastrointestinal encephalopathy; MLASA, myopathy-lactic acidosis-sideroblastic anemia; MP-MDS, myopathic MDS; MTS, Mohr-Tranebjaerg syndrome; NARP, neuropathy, ataxia, and retinitis pigmentosa; Ns, nonsyndromic MIDs; PAP, poor appetite; PC, pancreatitis; PCH, ponto-cerebellar hypoplasia; PS, Pearson syndrome; SANDO, sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; SCAE, spinocerebellar ataxia with epilepsy; VOM, vomiting; WS, Wolfram syndrome; XLASA, X-linked lactic acidosis and sideroblastic anemia.

### Constipation {#section7-1756283X16666806}

Constipation results from GI dysmotility and is one of the most frequent GI manifestations of MIDs. In single cases it may be of such an intensity that colectomy may be necessary \[[@bibr75-1756283X16666806]\]. Constipation has been particularly reported in MELAS \[[@bibr75-1756283X16666806]\], maternally inherited diabetes and deafness (MIDD) \[[@bibr7-1756283X16666806]\], autosomal dominant optic atrophy (ADOA) \[[@bibr11-1756283X16666806]\], Alpers--Huttenlocher disease (AHD) \[[@bibr22-1756283X16666806]\], and nonsyndromic MIDs \[[@bibr90-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). GI dysmotility with markedly delayed emptying and megacolon requiring surgery has been also reported in MNGIE \[[@bibr17-1756283X16666806]; [@bibr8-1756283X16666806]\]. Dietary measures are often ineffective and patients require regular administration of laxatives.

### Dysphagia {#section8-1756283X16666806}

Dysphagia may be due to CNS involvement, involvement of the peripheral nerves, or due to involvement of the smooth muscle cells in the underlying MID. Dysphagia in MIDs is common and may be progressive to such a degree that swallowing becomes impossible \[[@bibr28-1756283X16666806]\]. If dysphagia is associated with tongue atrophy, amyotrophic lateral sclerosis (ALS) must be considered as a differential \[[@bibr77-1756283X16666806]; [@bibr35-1756283X16666806]\]. Dysphagia may occur in syndromic MIDs as well as nonsyndromic MIDs. Among the syndromic MIDs it has been reported in myoclonic epilepsy with ragged-red fibers (MERRF) syndrome with brain stem stroke-like episodes \[[@bibr73-1756283X16666806]\], CPEO \[[@bibr105-1756283X16666806]; [@bibr78-1756283X16666806]; [@bibr72-1756283X16666806]\], KSS \[[@bibr40-1756283X16666806]; [@bibr51-1756283X16666806]\], Pearson syndrome (PS) \[[@bibr54-1756283X16666806]\], Leigh syndrome (LS) \[[@bibr59-1756283X16666806]\], PCH \[[@bibr92-1756283X16666806]\], Wolfram syndrome (WS) \[[@bibr79-1756283X16666806]\], Mohr--Tranebjaerg syndrome (MTS) \[[@bibr62-1756283X16666806]\], sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO) \[[@bibr94-1756283X16666806]; [@bibr38-1756283X16666806]\], or MNGIE \[[@bibr48-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). In a family carrying a mutation in the RNASEH1 gene, CPEO was accompanied by dysphagia, general weakness, and spinocerebellar ataxia \[[@bibr105-1756283X16666806]\].

The RNASEH1 gene encodes the RNAase H1, an endonuclease which acts in the nucleus and in mitochondria where it digests the RNA component of RNA/DNA hybrids. Patients carrying SPG7 mutations may not only present with CPEO but also with general myopathy, spasticity, ataxia, and dysphagia \[[@bibr78-1756283X16666806]\]. Dysphagia may be also part of the phenotype in patients carrying PEO1 mutations, which may additionally manifest with CPEO, general myopathy, and respiratory insufficiency \[[@bibr72-1756283X16666806]\]. In nonsyndromic MIDs, dysphagia was reported in an Italian female with multisystem disease due to a deletion in the cytb gene \[[@bibr14-1756283X16666806]\]. In patients carrying POLG1 mutations, dysphagia may be accompanied by CPEO, seizures, neuropathy, ataxia, hepatopathy, or migraine \[[@bibr104-1756283X16666806]\]. In a 6-year-old boy with a single mtDNA deletion manifesting as stroke-like episodes and Leigh-like neuropathology, dysphagia was one among numerous other phenotypic features \[[@bibr5-1756283X16666806]\].

### Vomiting {#section9-1756283X16666806}

Cyclic or episodic vomiting is a frequent GI manifestation of syndromic and nonsyndromic MIDs. Most well-known is MELAS syndrome in which vomiting can be one of the cardinal phenotypic manifestations or may be the presenting manifestation. Recurrent vomiting may be so strong that it is occasionally confused with bulimia \[[@bibr17-1756283X16666806]\]. Compared with cyclic vomiting syndrome, a putative MID, vomiting in MELAS, is less prominent. Migraine-like headache, a frequent CNS manifestation in various MIDs \[[@bibr102-1756283X16666806]\], is often associated with profuse and recurrent vomiting, intractable to standard therapy during the attacks. Other syndromic MIDs in which vomiting has been reported include KSS \[[@bibr46-1756283X16666806]\], PS \[[@bibr54-1756283X16666806]\], LS \[[@bibr57-1756283X16666806]\], MNGIE \[[@bibr17-1756283X16666806]; [@bibr6-1756283X16666806]\], myo-cerebro-hepatopathy syndrome (MCHS), a mitochondrial depletion syndrome (MDS) due to POLG1 mutations \[[@bibr63-1756283X16666806]; [@bibr74-1756283X16666806]\], and AHD \[[@bibr67-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). In nonsyndromic MIDs vomiting, together with other GI manifestations, has been reported in 3 of 6 patients with a nonsyndromic MID \[[@bibr17-1756283X16666806]\]. In a 16-year-old male with recurrent vomiting the Leigh-like phenotype was due to the primary Leber's hereditary optic neuropathy (LHON) mutation m.3460G\>A in the ND1 gene \[[@bibr55-1756283X16666806]\]. In patients with MNGIE, vomiting may occur only during the night \[[@bibr17-1756283X16666806]\]. In case recurrent vomiting lasts for months or even years, chronic malnutrition may ensue.

### Gastroparesis {#section10-1756283X16666806}

Gastroparesis is rather infrequent among MIDs but has been occasionally reported \[[@bibr47-1756283X16666806]; [@bibr19-1756283X16666806]\]. Gastroparesis may be due to affection of the smooth muscle cells by the metabolic defect or due to reduced parasympathetic innervation leading to sympathetic overstimulation. Gastroparesis results in gastric dysmotility with delayed gastric emptying and dilation of the stomach. Gastroparesis with delayed gastric emptying has been particularly reported in patients with nonsyndromic MIDs due to POLG1 mutations \[[@bibr13-1756283X16666806]\]. These patients additionally present with sensory-ataxic neuropathy, CPEO, and dysarthria \[[@bibr13-1756283X16666806]\]. Delayed gastric emptying was also reported in MID patients carrying the m.3243A\>G mutation \[[@bibr68-1756283X16666806]\]. Even children with nonsyndromic MIDs may present with delayed gastric emptying and prolonged intestinal transit time (ITT) \[[@bibr8-1756283X16666806]\]. Among the syndromic MIDs, a grossly dilated stomach has been most often reported in MNGIE patients. \[[@bibr17-1756283X16666806]\] and gastroparesis in SANDO \[[@bibr13-1756283X16666806]\]. Intractable gastroparesis may be also a phenotypic feature of pyruvate-dehydrogenase deficiency \[[@bibr95-1756283X16666806]\].

### Intestinal pseudo-obstruction {#section11-1756283X16666806}

Intestinal pseudo-obstruction is rare and characterized by recurrent episodes of bowel obstruction without a mechanical obstructive cause \[[@bibr30-1756283X16666806]\]. Intestinal pseudo-obstruction is actually 'the most severe form' of MIDs affecting GI motility. Intestinal pseudo-obstruction has to be differentiated from mechanical intestinal obstructive syndrome, which can be challenging, since both abnormalities present with similar clinical manifestations \[[@bibr101-1756283X16666806]\]. Intestinal pseudo-obstruction has been reported in syndromic and nonsyndromic MIDs but also in respiratory chain MIDs and nonrespiratory chain MIDs. Among the respiratory chain MIDs it has been found in MELAS \[[@bibr76-1756283X16666806]\], MERRF \[[@bibr85-1756283X16666806]\], MIDD \[[@bibr7-1756283X16666806]\], AHD \[[@bibr11-1756283X16666806]\], encephalo-myopathic MDS \[[@bibr89-1756283X16666806]\], and nonsyndromic MIDs \[[@bibr3-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). In patients with MELAS syndrome administration of phenytoin may trigger the development of intestinal pseudo-obstruction \[[@bibr20-1756283X16666806]\].

### Diarrhea {#section12-1756283X16666806}

GI dysmotility resulting in diarrhea has a similar frequency as constipation. Diarrhea in MIDs may be due to intestinal overactivity or exocrine pancreas insufficiency. Diarrhea may be also due to small intestinal bacteria overgrowth (SIBO). Diarrhea has been particularly reported in LS \[[@bibr99-1756283X16666806]\], MIDD \[[@bibr66-1756283X16666806]\], MNGIE \[[@bibr70-1756283X16666806]\], encephalomyopathic MDS \[[@bibr12-1756283X16666806]\], and nonsyndromic MIDs \[[@bibr8-1756283X16666806]; [@bibr97-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). In particular, patients with MNGIE may be easily satiated, nauseated, and may have an increased bowel frequency \[[@bibr17-1756283X16666806]\]. Other patients with MNGIE may present with intermittent diarrhea \[[@bibr17-1756283X16666806]\].

### Rare manifestations of gastrointestinal hollow organs {#section13-1756283X16666806}

Rare manifestations of GI hollow organs in MIDs include dry mouth (sicca syndrome, xerostomia) \[personal communication\], paradontosis \[[@bibr32-1756283X16666806]\], tracheoesophageal fistula \[[@bibr88-1756283X16666806]\], stenosis of the duodeno-jejunal junction \[[@bibr17-1756283X16666806]\], atresia or imperforate anus \[[@bibr88-1756283X16666806]\], congenital stenosis or obstruction of the GI tract with dilation of the pre-stenotic sections \[[@bibr17-1756283X16666806]\], recurrent bowel perforations with intra-abdominal abscesses \[[@bibr29-1756283X16666806]\], postprandial abdominal pain in MNGIE \[[@bibr8-1756283X16666806]; [@bibr11-1756283X16666806]\] or nonsyndromic MIDs \[[@bibr17-1756283X16666806]\], diverticulosis \[[@bibr71-1756283X16666806]\], or pneumatosis coli \[[@bibr17-1756283X16666806]\]. Whether rare GI manifestations of MIDs are more prevalent among MIDs than in the general population is unknown.

Abnormalities of gastrointestinal parenchymatous organs {#section14-1756283X16666806}
-------------------------------------------------------

### Pancreatitis {#section15-1756283X16666806}

Pancreatitis with or without diabetes and with or without exocrine pancreas insufficiency has been occasionally described in respiratory chain and nonrespiratory chain MID patients. Pancreatitis is usually of the aseptic type with a good tendency to recover but a high risk to recur. In some patients, pancreatitis may manifest exclusively as amylase or lipase elevation without clinical manifestations or abnormalities on imaging. The cause of pancreatitis in MIDs is unknown, but it can be speculated that the metabolic defect in exocrine pancreas cells promotes a defect in exocrine enzyme secretion, which could result in intracellular protease accumulation and activation. It is also conceivable that the composition of the pancreatic secretions is nonphysiological thus leading to obstruction of the exocrine pathways and consecutively to pancreatitis. MIDs in which pancreatitis has been reported include MELAS \[[@bibr50-1756283X16666806]\], MERRF \[[@bibr96-1756283X16666806]\], CPEO \[[@bibr50-1756283X16666806]\], KSS \[[@bibr24-1756283X16666806]\], PS \[[@bibr23-1756283X16666806]\], MIDD \[[@bibr84-1756283X16666806]\], AHD \[[@bibr64-1756283X16666806]\], and nonsyndromic MIDs \[[@bibr100-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}). Interestingly, pancreatitis has not been reported in MNGIE.

### Hepatopathy {#section16-1756283X16666806}

Involvement of the liver is a frequent phenotypic manifestation of MIDs and occurs as elevation of liver transaminases \[[@bibr41-1756283X16666806]\], as steatosis hepatis, hepatomegaly \[[@bibr63-1756283X16666806]\], fibrosis \[[@bibr63-1756283X16666806]\], as liver cysts, hepatoma, biliary malignancy, or as acute liver failure \[[@bibr10-1756283X16666806]\]. Liver involvement may occur in up to 20% of MID patients \[[@bibr21-1756283X16666806]\]. Liver involvement is more frequent in children compared with adults \[[@bibr9-1756283X16666806]\]. Steatosis or elevation of liver enzymes typically occurs in the absence of hyperlipidemia, intake of liver toxic drugs, a history of alcohol consumption, or antibodies against hepatitis viruses. Involvement of the liver may manifest clinically or may be subclinical \[[@bibr25-1756283X16666806]\]. In some patients, liver involvement becomes evident only after application of liver toxic medication \[[@bibr53-1756283X16666806]\]. It is also striking that many MID patients have a history of cholecystolithiasis or choledocholithiasis \[personal communication\]. Liver involvement occurs in syndromic and nonsyndromic MIDs. The most well-known among the syndromic MIDs are the MDSs, such as AHD or the hepato-cerebral MDS. Liver involvement has been also reported in respiratory chain MIDs such as MELAS \[[@bibr69-1756283X16666806]; [@bibr49-1756283X16666806]; [@bibr4-1756283X16666806]\], MERRF \[[@bibr58-1756283X16666806]\], CPEO \[[@bibr91-1756283X16666806]\], PS with progressive liver failure and steatosis \[[@bibr86-1756283X16666806]\], LS \[[@bibr56-1756283X16666806]\], PCH \[[@bibr81-1756283X16666806]\], 3-methyl-glutaconic aciduria, deafness, encephalopathy, and Leigh-like (MEDGEL) syndrome \[[@bibr82-1756283X16666806]\], mitochondrial recessive ataxia syndrome (MIRAS) \[[@bibr42-1756283X16666806]\], MNGIE (steatosis hepatis) \[[@bibr31-1756283X16666806]\], infantile-onset spinocerebellar ataxia (IOSCA) (elevated transaminases) \[[@bibr41-1756283X16666806]\], AHD \[[@bibr64-1756283X16666806]; [@bibr87-1756283X16666806]\], hepato-cerebral MDS \[[@bibr2-1756283X16666806]\], encephalomyopathic MDS \[[@bibr15-1756283X16666806]\], myopathic MDS \[[@bibr16-1756283X16666806]\], and in nonsyndromic MIDs \[[@bibr9-1756283X16666806]; [@bibr25-1756283X16666806]; [@bibr103-1756283X16666806]; [@bibr61-1756283X16666806]\] ([Table 2](#table2-1756283X16666806){ref-type="table"}) but also in nonrespiratory chain MIDs such as hyper-ornithinemia-hyper-ammonemia-homo-citrullinuria (HHH) syndrome \[[@bibr1-1756283X16666806]\]. Hepatopathy seems to be particularly prevalent among patients carrying POLG1 mutations \[[@bibr83-1756283X16666806]\]. Autopsy studies, as well as muscle biopsy analyses, have shown that in patients with MIDs the activity of respiratory chain complexes can be reduced \[[@bibr93-1756283X16666806]\].

### Rare manifestations of gastrointestinal parenchymatous organs {#section17-1756283X16666806}

Rare manifestations of GI parenchymatous organs in MIDs include liver cysts, pancreatic cysts \[[@bibr24-1756283X16666806]\], and pancreatic lipomatosis \[personal communication\], \[[@bibr32-1756283X16666806]\]. Whether these GI manifestations of MIDs are more prevalent among MIDs than in the general population is unknown.

Complications of abnormal gastrointestinal function {#section18-1756283X16666806}
---------------------------------------------------

Complications of abnormal GI function in MIDs include chronic aspiration and consecutive pneumonia in cases of GI stenosis, dysmotility, achalasia, or obstruction, gastroesophageal reflux, malnutrition with polyneuropathy, or bacterial GI infections \[[@bibr17-1756283X16666806]\]. In cases of recurrent vomiting, electrolyte disturbances, exsiccosis, hypokalemia, and hypochloremic alkalosis may ensue. Secondary GI infection may be another complication of GI dysmotility.

Treatment {#section19-1756283X16666806}
---------

Generally, treatment of GI manifestations in MIDs may be symptomatic or causative, noninvasive or invasive, surgical or nonsurgical. In the vast majority of cases, GI involvement in MIDs can be treated only by symptomatic measures. Only for MNGIE is a causal therapy with bone marrow transplantation available \[[@bibr43-1756283X16666806]\].

### Noninvasive treatment {#section20-1756283X16666806}

Mainstays of treating GI abnormalities in MIDs include treatment of constipation, enteral nutrition, including tube feeding, tricyclic antidepressants for chronic irritable bowel syndrome-type pain, and treatment of vomiting and cyclic vomiting. Dietary measures may play a supplementary role. Particularly in patients with hepatic involvement, pancreatitis, dysphagia, constipation, or diarrhea, an appropriate diet can support recovery. Appetite stimulation is also a key among those who swallow normally. In cases where the GI tract shuts down, metabolic stabilization can be achieved by intravenous glucose administration. In cases of dysphagia or low appetite due to mood disorders, application of antidepressants can be helpful. In case of noninfectious diarrhea, application of carbo medicinalis or loperamide may be indicated. More challenging is the treatment of cyclic vomiting syndrome during an episode, which may include lorazepam, ondansetron, or zolmitriptan in cases of abdominal cramping \[[@bibr34-1756283X16666806]\]. In cases of constipation, domperidone (20 mg/day) or laxatives may be helpful. In cases of secondary infection of the GI tract, application of an appropriate antibiotic after identification of the causative agent by a stool culture may be effective. Patients with postprandial abdominal pain may benefit from treatment with antispasmodics or proton-pump inhibitors. If there is pain from reflux esophagitis, application of proton-pump inhibitors, H2-blockers, or sucralfate can be helpful. Children with abdominal pain may profit from amitriptyline, but the mitochondrion-toxic side effects of this compound \[e.g. causes coenzyme-Q (CoQ) deficiency, reduces the mitochondrial membrane potential, causes oxidative stress, blocks citrate synthetase\] have to be considered \[[@bibr65-1756283X16666806]\]. Patients with aseptic pancreatitis and exocrine pancreas insufficiency may benefit from the substitution of pancreas enzymes. This may also have a beneficial effect on diarrhea if this is due to exocrine pancreas insufficiency.

Whether the application of CoQ, idebenone, vitamins, co-factors, L-arginine, succinate, or L-carnitine, frequently given in MIDs, also have a beneficial effect on GI manifestations of MIDs is largely unknown, but it can be speculated that they may exert a positive effect also in this indication in some of the patients. The putative beneficial effect of these agents may be also attributable to a placebo effect. However, no randomized-controlled studies are available to solve these issues. One of the most important measures to treat GI manifestations of MIDs is the avoidance of mitochondrion-toxic drugs, such as chloramphenicol, aminoglycosides, linezolide, valproic acid, nucleoside reverse transcriptase inhibitors, dichloroacetate, carbamazepine, phenytoin, phenobarbital, or statins. \[[@bibr40-1756283X16666806]\], which is not well known by many of the treating physicians. Valproic acid should not be given to patients with AHD or other MIDs with liver involvement, since it may cause acute liver failure particularly in patients carrying POLG1 mutations.

### Invasive treatment {#section21-1756283X16666806}

In cases of cachexia or malnourishment or a failure to thrive, implementation of a percutaneous gastrostomy (PEG) or temporary insertion of a nasogastric tube can be inevitable. In cases of congenital stenosis or obstruction the most adequate measure to solve the problem is surgery. In cases of diverticulosis or recurrent diverticulitis, surgical resection of the affected section may be indicated. In cases of severe constipation or dysmotility or megacolon colectomy may be the only option. Stem cell therapy of MNGIE is carried by infusion of bone-marrow derived hematopoietic stem cells as a source of thymidine phosphorylase \[[@bibr43-1756283X16666806]\]. In cases of severe constipation colectomy or colostomy may be beneficial.

Clinical implications and conclusion {#section22-1756283X16666806}
====================================

GI manifestations of MIDs are manifold and need to be recognized in order to support the work-up for establishing the diagnosis. Typical MID manifestations are dysphagia, vomiting, GI sphincter dysfunction, reduced contractility or increased contractility of the GI tract, hepatopathy, pancreatitis, and congenital obstruction. GI manifestations of MIDs may be the dominant or nondominant phenotypic feature. GI problems may be the sole manifestation of a MID or one among others. Diagnostic work-up needs to be intensified if a MID is suspected to establish the correct diagnosis and to initiate appropriate symptomatic treatment in due time. For MNGIE a more causal therapy is available, which is more effective the earlier it is initiated. Early diagnosis of a MID is thus important and GI manifestations can contribute to raise the suspicion of a MID and, if part of a MIMODS, strongly support the diagnosis. Neurologists and gastroenterologists must be aware of the fact that GI symptoms and signs may be attributable to a MID particularly if clinical or subclinical manifestations are present also in other systems. Since avoidance of mitochondrion-toxic drugs is one of the key measures to treat MIDs, it is important to exclude a MID as the cause of GI symptoms and signs and not to worsen GI manifestations by application of mitochondrion-toxic drugs. Overall, it is important to note that GI manifestations may be useful in the diagnosis of MIDs (e.g. in patients with motility disorders), but also need to be anticipated so that complications can be managed.
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